Drug Profile
EPI-HNE2
Latest Information Update: 23 Nov 2004
Price :
$50
*
At a glance
- Originator Dyax
- Class Radiopharmaceutical diagnostics
- Mechanism of Action Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 23 Nov 2004 No development reported - Preclinical for Inflammation (diagnosis) in USA (unspecified route)
- 17 Sep 2002 Preclinical trials in Inflammation (diagnosis) (unspecified route)
- 18 Jul 2001 Preclinical development for Inflammation (diagnosis) in USA (unspecified route)